ATE363074T1 - Substrate und screeningverfahren für transportproteine - Google Patents
Substrate und screeningverfahren für transportproteineInfo
- Publication number
- ATE363074T1 ATE363074T1 AT00966735T AT00966735T ATE363074T1 AT E363074 T1 ATE363074 T1 AT E363074T1 AT 00966735 T AT00966735 T AT 00966735T AT 00966735 T AT00966735 T AT 00966735T AT E363074 T1 ATE363074 T1 AT E363074T1
- Authority
- AT
- Austria
- Prior art keywords
- transport proteins
- substrates
- screening methods
- methods
- screening
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15407199P | 1999-09-14 | 1999-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE363074T1 true ATE363074T1 (de) | 2007-06-15 |
Family
ID=22549879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00966735T ATE363074T1 (de) | 1999-09-14 | 2000-09-14 | Substrate und screeningverfahren für transportproteine |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7413536B1 (de) |
| EP (1) | EP1212619B1 (de) |
| AT (1) | ATE363074T1 (de) |
| AU (1) | AU7703400A (de) |
| DE (1) | DE60034954D1 (de) |
| WO (1) | WO2001020331A1 (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001076531A2 (en) * | 2000-04-07 | 2001-10-18 | University Of Maryland, Baltimore | Bile acid containing prodrugs with enhanced bioavailability |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| SI1775305T1 (sl) | 2000-08-05 | 2015-01-30 | Glaxo Group Limited | S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| AU2002230398A1 (en) | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| KR100831534B1 (ko) | 2001-04-30 | 2008-05-22 | 글락소 그룹 리미티드 | 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체 |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| AU2002345638A1 (en) | 2001-06-11 | 2002-12-23 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| EP1406493A4 (de) | 2001-06-11 | 2006-06-14 | Xenoport Inc | Verabreichung von mitteln über den pept-2-transporter |
| US7026166B2 (en) * | 2002-01-22 | 2006-04-11 | Chiron Corporation | Fluorogenic dyes |
| AU2003219770B2 (en) | 2002-02-15 | 2008-10-09 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| AU2003243180A1 (en) | 2002-05-17 | 2003-12-12 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| FR2840994B1 (fr) * | 2003-01-22 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
| EP1509769A2 (de) * | 2002-05-31 | 2005-03-02 | Commissariat A L'energie Atomique | Verfahren zum screening von gruppen radioaktiver moleküle und anwendungen dafür |
| FR2840407B1 (fr) * | 2002-05-31 | 2008-07-18 | Commissariat Energie Atomique | Methode de criblage de banques de biomolecules et ses applications |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US20040161424A1 (en) * | 2002-10-08 | 2004-08-19 | Xenoport | Human organic solute transporters |
| WO2004041203A2 (en) | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| US7704756B2 (en) | 2003-01-21 | 2010-04-27 | Novartis Vaccines And Diagnostics, Inc. | Fluorogenic dyes |
| US7452680B2 (en) | 2004-01-30 | 2008-11-18 | Xenoport, Inc. | MCT1 transporters expressed in blood brain barrier cells |
| TWI351284B (en) * | 2004-04-09 | 2011-11-01 | Chugai Pharmaceutical Co Ltd | Novel water-soluble prodrugs |
| DE602005010270D1 (de) | 2004-07-12 | 2008-11-20 | Xenoport Inc | Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon |
| US7241807B2 (en) | 2004-07-12 | 2007-07-10 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| WO2007038659A1 (en) * | 2005-09-26 | 2007-04-05 | Invitrogen Corporation | Violet laser excitable dyes and their method of use |
| KR20080093036A (ko) * | 2006-01-31 | 2008-10-17 | 사노피-아벤티스 | 유기 양이온 수송체의 활성을 측정하는 방법 |
| WO2007098037A2 (en) * | 2006-02-17 | 2007-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sequential reporter enzyme luminescence (srl) methods and compositions for practicing the same |
| AU2007239679B2 (en) | 2006-04-13 | 2012-10-11 | Chugai Seiyaku Kabushiki Kaisha | Taurine transporter gene |
| US8058260B2 (en) | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
| WO2008073856A2 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
| JP5635260B2 (ja) | 2007-03-15 | 2014-12-03 | 中外製薬株式会社 | ポリペプチドの製造方法 |
| KR101577839B1 (ko) | 2007-08-07 | 2015-12-15 | 추가이 세이야쿠 가부시키가이샤 | 이종 단백질의 제조 방법 |
| WO2009051109A1 (ja) | 2007-10-15 | 2009-04-23 | Chugai Seiyaku Kabushiki Kaisha | 異種タンパク質を高生産する細胞の作製方法 |
| ES2548294T3 (es) * | 2007-10-24 | 2015-10-15 | Chugai Seiyaku Kabushiki Kaisha | Célula para su uso en la producción de proteína exógena, y procedimiento de producción usando la célula |
| EP2276479B1 (de) | 2008-04-15 | 2014-07-02 | SineVir Therapeutics LLC | Prodrugs von neuraminidasehemmern |
| JP2012517811A (ja) * | 2009-02-13 | 2012-08-09 | エックス−ボディ インコーポレイテッド | Dnaディスプレイを利用した核酸送達ビヒクルの同定方法 |
| ES2638324T3 (es) | 2009-02-13 | 2017-10-19 | X-Chem, Inc. | Métodos de creación y examen de bibliotecas codificadas por ADN |
| EP2423309B1 (de) | 2009-04-22 | 2018-01-03 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur herstellung einer zelle mit hoher produktion heterogener proteine |
| CA2768352C (en) * | 2009-07-16 | 2016-10-11 | Beckman Coulter, Inc. | Novel fluorescent dyes and uses thereof |
| JP5561692B2 (ja) * | 2010-03-09 | 2014-07-30 | 国立大学法人群馬大学 | 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法 |
| ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| US8399262B2 (en) | 2011-03-23 | 2013-03-19 | Darrel A. Mazzari | Biosensor |
| IN2014CN02574A (de) | 2011-09-07 | 2015-06-26 | Chem Inc X | |
| US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| AU2012328526B2 (en) | 2011-10-28 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| SG10201907347YA (en) | 2012-07-13 | 2019-09-27 | X Chem Inc | Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases |
| CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| AU2014229050A1 (en) | 2013-03-15 | 2015-10-22 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease |
| BR112018011503A2 (pt) | 2015-12-07 | 2018-12-04 | Zymergen Inc | promotores da corynebacterium glutamicum |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| EP3478845A4 (de) * | 2016-06-30 | 2019-07-31 | Zymergen, Inc. | Verfahren zur erzeugung einer glucose-permease-bibliothek und verwendungen davon |
| US10544390B2 (en) | 2016-06-30 | 2020-01-28 | Zymergen Inc. | Methods for generating a bacterial hemoglobin library and uses thereof |
| GB2552460A (en) * | 2016-07-11 | 2018-01-31 | Evox Therapeutics Ltd | CPP-Mediated EV Loading |
| EP3923943B1 (de) | 2019-02-12 | 2024-07-31 | Mirum Pharmaceuticals, Inc. | Genotyp und dosisabhängige reaktion auf einen asbti bei patienten mit gallensalzexportpumpenmangel |
| WO2021023100A1 (zh) * | 2019-08-06 | 2021-02-11 | 杜心赟 | 脱氧胆酸类化合物、药物组合物及其用途 |
| EP4049032A1 (de) | 2019-10-25 | 2022-08-31 | Cercacor Laboratories, Inc. | Indikatorverbindungen, vorrichtungen, die indikatorverbindungen umfassen, und verfahren zur herstellung und verwendung derselben |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5569678A (en) * | 1989-07-31 | 1996-10-29 | Massachusetts Institute Of Technology | Control of wound scar production |
| DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5866123A (en) | 1990-04-13 | 1999-02-02 | Research Development Foundation | Gene encoding cationic amino acid transporter protein |
| US5236902A (en) * | 1990-11-26 | 1993-08-17 | The Governors Of The University Of Alberta | Method and probes for detecting nucleoside transporter and method for producing the probes |
| US5580775A (en) | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
| US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| DE4222315A1 (de) | 1992-07-05 | 1994-01-13 | Inst Genbiologische Forschung | DNA-Sequenzen für Aminosäuretransporter, Plasmide, Bakterien, Hefen und Pflanzen enthaltend einen Transporter |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5658782A (en) | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
| DE4343527A1 (de) | 1993-12-16 | 1995-06-22 | Schering Ag | Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung |
| US5589358A (en) | 1993-12-29 | 1996-12-31 | Univ Wake Forest | Ileal bile acid transporter compositions and methods |
| US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
| CZ143897A3 (cs) * | 1994-11-12 | 1998-04-15 | Basf Aktiengesellschaft | Způsob výroby aminů ze sloučenin obsahujících alespoň tři kyanové skupiny |
| CA2219136A1 (en) * | 1995-04-24 | 1996-10-31 | Chromaxome Corp. | Methods for generating and screening novel metabolic pathways |
| JP3900305B2 (ja) | 1995-09-11 | 2007-04-04 | ザ バーナム インスティテュート | インビボにおいて選択された器官または組織に帰巣する分子および同分子を同定する方法 |
| AU705688B2 (en) | 1995-11-10 | 1999-05-27 | Cytogen Corporation | Peptides which enhance transport across tissues and methods of identifying and using the same |
| US5780264A (en) | 1996-06-06 | 1998-07-14 | The President And Fellows Of Harvard College | Iron transport protein |
| EP0923603A1 (de) * | 1996-07-16 | 1999-06-23 | Novo Nordisk A/S | Oligopeptid-transporter |
| US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| CA2282658C (en) | 1997-02-27 | 2003-02-25 | Cellomics, Inc. | A system for cell-based screening |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| JP4129298B2 (ja) * | 1997-05-15 | 2008-08-06 | サイトジェン コーポレーション | 胃腸管(git)輸送受容体に結合するランダムペプチド、及び関連した方法 |
| JP4044728B2 (ja) * | 1997-07-15 | 2008-02-06 | メディクエスト セラピューティックス インク | 治療および診断薬剤としての新規なポリアミンアナログ |
-
2000
- 2000-09-14 US US09/661,927 patent/US7413536B1/en not_active Expired - Fee Related
- 2000-09-14 AU AU77034/00A patent/AU7703400A/en not_active Abandoned
- 2000-09-14 AT AT00966735T patent/ATE363074T1/de not_active IP Right Cessation
- 2000-09-14 DE DE60034954T patent/DE60034954D1/de not_active Expired - Lifetime
- 2000-09-14 EP EP00966735A patent/EP1212619B1/de not_active Expired - Lifetime
- 2000-09-14 WO PCT/US2000/025439 patent/WO2001020331A1/en not_active Ceased
-
2008
- 2008-07-14 US US12/172,801 patent/US20090221442A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1212619A1 (de) | 2002-06-12 |
| WO2001020331A1 (en) | 2001-03-22 |
| DE60034954D1 (de) | 2007-07-05 |
| US20090221442A1 (en) | 2009-09-03 |
| AU7703400A (en) | 2001-04-17 |
| US7413536B1 (en) | 2008-08-19 |
| EP1212619B1 (de) | 2007-05-23 |
| WO2001020331A9 (en) | 2002-10-03 |
| EP1212619A4 (de) | 2004-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE363074T1 (de) | Substrate und screeningverfahren für transportproteine | |
| NO20043245L (no) | Bindingsproteiner som biosensorer | |
| EP1687283A4 (de) | Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung | |
| ATE295347T1 (de) | Stoffe und zusammensetzungen für die verabreichung aktiver substanzen | |
| DE60137203D1 (de) | Poröse ferro- oder ferrimagnetische glasteilchen für molekültrennung | |
| DK1053256T3 (da) | Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf | |
| DE60005787D1 (de) | Wasserlösliche rhodaminfarbstoffe und ihre konjugate | |
| ATE233762T1 (de) | Bicyclische polyamiosaure metallkomplexe, verfahren zu ihrer herstellung und ihre verwendung für medizinische bilderzeugung | |
| ATE294164T1 (de) | Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening | |
| DE60126337D1 (de) | Verfahren zum screenen für gpr40-liganden | |
| TR200101663T2 (tr) | Pro-kollajen c-proteinaz inhibitörleri | |
| DE59806371D1 (de) | Kontrastmittel für das infarkt- und nekroseimaging | |
| WO1999050459A3 (en) | High throughput in vitro screening assays for transcription modulators | |
| DK1049721T3 (da) | Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse | |
| MXPA03001536A (es) | (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen. | |
| MXPA03011898A (es) | Ensayo de seleccion in vitro para ?- secretasa. | |
| WO2001008707A3 (de) | Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen | |
| ATE252574T1 (de) | Benzofuran-2-ones als färbemittel für organische materialien | |
| ATE501274T1 (de) | Cucurbiturilderivat-gebundenes feststoffsubstrat und biochip unter verwendung davon | |
| ATE256120T1 (de) | Reagentien für cyp2d fluoreszenztest | |
| AU2001264163A1 (en) | Lipid uptake assays | |
| MXPA04004018A (es) | Metodos de separacion por exclusion para toxicidad de compuestos de prueba. | |
| NO20025738D0 (no) | Metode | |
| DK1171444T3 (da) | Pyridothienodiazepiner, fremgangsmåde til fremstilling af disse og farmaceutiske præparater indeholdende disse | |
| DE60332076D1 (de) | Doppelmessverfahren zur Anzeige des Inhalts von Poststücken |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |